Aller au contenu principal
xMedica

NCT07570316ClinicalTrials.gov

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is…

Phase 3230 participants recherchés35 sites3 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-05-06; recorded start 2026-06-10
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 87 other studies in this databaseCounted from the lead sponsor named in the record (argenx)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 18 sites

  • Data monitoring committee0/7

    Data monitoring committee not stated in the record

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 230 participants (target), run at 35 sites, across 3 countries.

How this score is built
  • Enrolment23/40

    230 participants (target)

  • Site count15/25

    18 sites

  • Country count7/15

    2 countries

  • Planned duration9/10

    Planned over about 47 months

  • Sponsor scale7/10

    argenx has led 83 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Affections

  • Graves' Disease
  • Graves Disease

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF. * Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels \>=ULN (upper limit of normal) at screening. * Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) \<0.1 mIU/L at screening. * Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening. Exclusion Criteria: * History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter). * History of RAI (radioactive iodine) therapy or received a total thyroidectomy. * T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received \<6 weeks before screening. * Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications. * Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement230 participants recherchés

Promoteur et collaborateurs

  • argenx Promoteur

Groupes et interventions

  • Part A - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

  • Part A - placebo PH20 SC PFSPLACEBO_COMPARATOR

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

  • Part B - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

  • Part B - placebo PH20 SC PFSEXPERIMENTAL

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

  • Part C - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period

Interventions

  • Produit biologique Efgartigimod PH20 SC

    Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

  • Autre Placebo PH20 SC

    Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)

Critères de jugement

  1. Critère de jugement principal

    Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A

    Free triiodothyronine: \[fT3\]; free thyroxine: \[fT4\]; ATDs: antithyroid drugs

    Délai Up to 24 weeks (part A)

  2. Critère de jugement secondaire

    Time to becoming euthyroid off ATDs in part A

    ATDs: antithyroid drugs

    Délai Up to 24 weeks (part A)

  3. Critère de jugement secondaire

    Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A

    MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

    Délai Up to 24 weeks (part A)

  4. Critère de jugement secondaire

    Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A

    ULN : upper limit of normal; ATDs: antithyroid drugs.

    Délai Up to 24 weeks (part A)

  5. Critère de jugement secondaire

    Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A

    TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs.

    Délai Up to 24 weeks (part A)

  6. Critère de jugement secondaire

    Time to becoming euthyroid off ATDs and TRAb seronegative

    ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies.

    Délai Up to 24 weeks (part A) + up to 135 weeks

  7. Critère de jugement secondaire

    Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)

    ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

    Délai Up to 24 weeks (Part A)

  8. Critère de jugement secondaire

    Time to becoming euthyroid

    Délai Up to 24 weeks (part A) + up to 135 weeks

  9. Critère de jugement secondaire

    Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)

    TSH: thyroid-stimulating hormone; LLN: lower limit of normal.

    Délai Up to 24 weeks (part A)

  10. Critère de jugement secondaire

    Percentage of participants who remain euthyroid without ATDs

    ATDs: antithyroid drug

    Délai Up to 74 weeks (part B)

  11. Critère de jugement secondaire

    Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months

    ATDs: antithyroid drug

    Délai Up to 74 weeks (part B) + up to 135 weeks

  12. Critère de jugement secondaire

    Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS

    ATDs: antithyroid drug

    Délai Up to 72 weeks (part C)

  13. Critère de jugement secondaire

    Incidence of AEs and SAEs

    AEs: adverse events ; SAEs: serious adverse events.

    Délai Up to 135 weeks

  14. Critère de jugement secondaire

    Change in ThyPRO-39 over time

    The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status.

    Délai Up to 135 weeks

  15. Critère de jugement secondaire

    Change in PROMIS-PF10a over time

    The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function.

    Délai Up to 135 weeks

  16. Critère de jugement secondaire

    Efgartigimod serum concentrations over time

    Délai Up to 24 weeks (part A) + 72 weeks (part C)

  17. Critère de jugement secondaire

    Percentage change from baseline in total IgG levels in serum over time

    IgG: immunoglobulin G

    Délai Up to 98 weeks

  18. Critère de jugement secondaire

    Percentage change from baseline in TRAb serum levels over time

    TRAb: anti-TSHR autoantibodies.

    Délai Up to 135 weeks

  19. Critère de jugement secondaire

    Incidence of ADA against efgartigimod in serum

    ADA: antidrug antibody(ies)

    Délai Up to 24 weeks (part A) + up to 135 weeks

  20. Critère de jugement secondaire

    Incidence of antibodies against rHuPH20 in plasma

    rHuPH20: recombinant human hyaluronidase PH20

    Délai Up to 24 weeks (part A) + Up to 135 weeks

  21. Critère de jugement secondaire

    Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma

    NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20.

    Délai Up to 24 weeks (part A) + up to 135 weeks

Dates

Dates
Date de début10 juin 2026 (réelle)
Achèvement principal1 juin 2028 (estimée)
Achèvement1 mai 2030 (estimée)
Première publication6 mai 2026 (réelle)
Dernière mise à jour3 novembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisseptembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

35 sites sont en recrutement

Georgia

Georgia
ÉtablissementVilleÉtat ou régionStatut
LLC American Hospital NetworkTbilisiEn recrutement
In Vitro Fertilization Center LLCTbilisiEn recrutement
LLC Todua ClinicTbilisiEn recrutement
New HospitalsTbilisiEn recrutement
LTD Israeli-Georgian Medical Research Clinic HealthycoreTbilisiEn recrutement

United Kingdom

United Kingdom
ÉtablissementVilleÉtat ou régionStatut
Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)GatesheadTyne and WearEn recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Albany Medical College Community EndocrinologyAlbanyNew YorkEn recrutement
University of MichiganAnn ArborMichiganEn recrutement
Asheville Clinical ResearchAshevilleNorth CarolinaEn recrutement
Profound Research LLC at Tri-City Primary CareCarlsbadCaliforniaEn recrutement
Research Institute of DallasDallasTexasEn recrutement
Metro Detroit Endocrinology CenterDearbornMichiganEn recrutement
Frontier Medical Center - Academy of Diabetes Thyroid and EndocrineEl PasoTexasEn recrutement
Profound ResearchFarmington HillsMichiganEn recrutement
Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park LocationFleming IslandFloridaEn recrutement
The Center for Diabetes and Endocrine CareFort LauderdaleFloridaEn recrutement
Juno ResearchHoustonTexasEn recrutement
Clinic of EndocrinologyHoustonTexasEn recrutement
Tekton Research IrvingIrvingTexasEn recrutement
University of Florida Jacksonville College of MedicineJacksonvilleFloridaEn recrutement
Truman Medical CenterKansas CityMissouriEn recrutement
Ilumina Medical Research LLCKissimmeeFloridaEn recrutement
Johnson County Clin-Trials, Inc.LenexaKansasEn recrutement
Biopharma Informatic, LLCMcAllenTexasEn recrutement
Tekton Research - McKinneyMcKinneyTexasEn recrutement
Southern Endocrinology Associates PAMesquiteTexasEn recrutement
Oceane 7 Medical & Research Center, IncMiamiFloridaEn recrutement
Endocrine Associates of West Village PCNew YorkNew YorkEn recrutement
Diabetes Associates Medical GroupOrangeCaliforniaEn recrutement
Havana Research Institute LLC.PasadenaCaliforniaEn recrutement
Pasadena Clinical TrialsPasadenaCaliforniaEn recrutement
Wake Internal Medicine ConsultantsRaleighNorth CarolinaEn recrutement
San Jose Clinical TrialsSan JoseCaliforniaEn recrutement
Consano Clinical ResearchShavano ParkTexasEn recrutement
Alliance for Multispecialty Research, LLCWichitaKansasEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 3 novembre 2026

    Site ajouté

    3 sites added (35 total)

    3235

  2. 16 octobre 2026

    Site ajouté

    6 sites added (32 total)

    2632

  3. 22 septembre 2026

    Site ajouté

    3 sites added (26 total)

    2326

  4. 17 septembre 2026

    Site ajouté

    1 site added (23 total)

    2223

  5. 12 août 2026

    Site ajouté

    4 sites added (22 total)

    1822